# PDUFA dates January 2027: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2027-01

> 48 FDA catalysts are dated in January 2027, including 8 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in January 2027?

PDUFA dates in January 2027: IBTROZI (taletrectinib, NUVB) on January 4, 2027; ImmunityBio, Inc. (IBRX) on January 6, 2027; ANKTIVA (inbakicept, IBRX) on January 6, 2027; z-rostudirsen (DYN) on January 21, 2027; INSMED Inc (INSM) on January 28, 2027; Cerebrum (cerebrum, PRAX) on January 29, 2027; and 2 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2027-01)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-447321, https://www.sec.gov/Archives/edgar/data/1811063/000119312526447321/d371447dex991.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/fda-calendar/2027-01#answer

## PDUFA dates in January 2027

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| January 4, 2027 | Nuvation Bio Inc. | NUVB | IBTROZI (taletrectinib) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312526447321/d371447dex991.htm) |
| January 6, 2027 | ImmunityBio, Inc. | IBRX |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000079/ibrx-20260630.htm) |
| January 6, 2027 | ImmunityBio, Inc. | IBRX | ANKTIVA (inbakicept) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000079/ibrx-20260630.htm) |
| January 21, 2027 | Dyne Therapeutics, Inc. | DYN | z-rostudirsen |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000181879426000013/dyn-ex99_1.htm) |
| January 28, 2027 | INSMED Inc | INSM |  | MAC lung disease | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126041097/ef20084500_ex99-2.htm) |
| January 29, 2027 | Praxis Precision Medicines, Inc. | PRAX | Cerebrum (cerebrum) | essential tremor, or ET | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000089/prax-20260930.htm) |
| January 30, 2027 | Pharming Group N.V. | PHAR | Joenja® (leniolisib) |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000049/a2026q3pressrelease.htm) |
| January 30, 2027 | Pharming Group N.V. | PHAR |  |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000041/pharmingannouncesusfdaacce.htm) |

## All catalysts in January 2027

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 2027 | [TPOXX® (tecovirimat) primary completion](https://sec-api.dev/pdufa/tecovirimat) | SIGA | Smallpox | scheduled | "NCT04957485 (Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-01 (ESTIMATED); Lead Sponsor SIGA Technologies." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04957485)) |
| January 4, 2027 | [IBTROZI (taletrectinib) PDUFA date](https://sec-api.dev/pdufa/taletrectinib) | NUVB |  | scheduled | "In September 2026, Nuvation Bio announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for IBTROZI, four months ahead of the January 4, 2027, target action date." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312526447321/d371447dex991.htm)) |
| January 2027 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Arthritis, Psoriatic | scheduled | "NCT06641089 (Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-04 (ESTIMATED); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06641089)) |
| January 2027 | [AZD0780 primary completion](https://sec-api.dev/pdufa/azd0780) | AZN | Heterozygous Familial Hypercholesterolaemia | scheduled | "NCT07000136 (A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07000136)) |
| January 6, 2027 | [ImmunityBio, Inc. PDUFA date](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | scheduled | "In addition, while we have pursued additional regulatory submissions in the first quarter of 2026, such as a refiling of our sBLA after a submission in 2025 for BCG-unresponsive NMIBC patients in the papillary indication for which we received a PDUFA target action date of January 6, 2027, and are pursuing and anticipating certain additional regulatory submissions in 2026 and beyond following ongoing discussions with the FDA and other international regulatory agencies, the regulatory review process is dynamic and highly uncertain." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000079/ibrx-20260630.htm)) |
| January 6, 2027 | [ANKTIVA (inbakicept) PDUFA date](https://sec-api.dev/pdufa/inbakicept) | IBRX |  | scheduled | "In May 2026, we announced the FDA accepted for review our sBLA for ANKTIVA indicated with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with papillary tumors without CIS and assigned a PDUFA target action date of January 6, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1326110/000132611026000079/ibrx-20260630.htm)) |
| January 2027 | [Anifrolumab (blinded) primary completion](https://sec-api.dev/pdufa/anifrolumab-blinded) | AZN | Systemic Sclerosis; Scleroderma | scheduled | "NCT05925803 (Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05925803)) |
| January 2027 | [PCV21 primary completion](https://sec-api.dev/pdufa/pcv21) | SNY | Sickle Cell Disease | scheduled | "NCT07247188 (Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-07 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07247188)) |
| January 2027 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-Small Cell Lung Cancer | scheduled | "NCT05221840 (A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-08 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05221840)) |
| January 2027 | [Otx-tki primary completion](https://sec-api.dev/pdufa/otx-tki) | OCUL | Neovascular Age-related Macular Degeneration | scheduled | "NCT06495918 (Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-08 (ESTIMATED); Lead Sponsor Ocular Therapeutix, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06495918)) |
| January 2027 | [Pomalyst (pomalidomide) primary completion](https://sec-api.dev/pdufa/pomalidomide) | BMY | Relapsed or Refractory Multiple Myeloma | scheduled | "NCT05519085 (A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-10 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05519085)) |
| January 2027 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Metastatic Non-small Cell Lung Cancer | scheduled | "NCT06417814 (A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06417814)) |
| January 2027 | [AZD0780 primary completion](https://sec-api.dev/pdufa/azd0780) | AZN | Cardiovascular Disease | scheduled | "NCT07000123 (A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07000123)) |
| January 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT05609968 (Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05609968)) |
| January 2027 | [Adjuvanted rsvpref3 vaccine primary completion](https://sec-api.dev/pdufa/adjuvanted-rsvpref3-vaccine) | GSK | Respiratory Syncytial Virus Infections | scheduled | "NCT07092865 (A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-12 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07092865)) |
| January 2027 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT06706817 (A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06706817)) |
| January 2027 | [UBT251 primary completion](https://sec-api.dev/pdufa/ubt251) | NVO | Overweight; Obesity | scheduled | "NCT07395687 (A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-01-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07395687)) |
| January 2027 | [9vhpv vaccine primary completion](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Papillomavirus Infections | scheduled | "NCT04199689 (Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04199689)) |
| January 2027 | [Fianlimab primary completion](https://sec-api.dev/pdufa/fianlimab) | REGN | Melanoma | scheduled | "NCT05608291 (A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05608291)) |
| January 2027 | [Darovasertib primary completion](https://sec-api.dev/pdufa/darovasertib) | IDYA | Metastatic Uveal Melanoma | scheduled | "NCT05987332 (IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor IDEAYA Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05987332)) |
| January 2027 | [Natrunix 400 mg primary completion](https://sec-api.dev/pdufa/natrunix) | XBIT | Rheumatoid Arthritis | scheduled | "NCT06590090 (Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor XBiotech, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06590090)) |
| January 2027 | [Rsvpref primary completion](https://sec-api.dev/pdufa/rsvpref) | PFE | Lower Respiratory Tract Illness | scheduled | "NCT05035212 (Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-18 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05035212)) |
| January 2027 | [Livtencity (maribavir) primary completion](https://sec-api.dev/pdufa/maribavir) | TAK | Cytomegalovirus (CMV) | scheduled | "NCT05319353 (A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-18 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05319353)) |
| January 2027 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Lung Cancer | scheduled | "NCT05374603 (Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05374603)) |
| January 2027 | [GX-03 primary completion](https://sec-api.dev/pdufa/gx-03) | TTRX | Eczema Atopic Dermatitis; Eczema; Atopic Dermatitis | scheduled | "NCT07355075 (A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-01-20 (ESTIMATED); Lead Sponsor Turn Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07355075)) |
| January 21, 2027 | [Z-rostudirsen PDUFA date](https://sec-api.dev/pdufa/z-rostudirsen) | DYN |  | scheduled | "- Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000181879426000013/dyn-ex99_1.htm)) |
| January 2027 | [BRIUMVI® (ublituximab) primary completion](https://sec-api.dev/pdufa/ublituximab) | TGTX | Relapsing Multiple Sclerosis | scheduled | "NCT05877963 (Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-21 (ESTIMATED); Lead Sponsor TG Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05877963)) |
| January 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity | scheduled | "NCT06858839 (Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-21 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06858839)) |
| January 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | scheduled | "NCT06858878 (Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-21 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06858878)) |
| January 2027 | [JOURNAVX (suzetrigine) primary completion](https://sec-api.dev/pdufa/suzetrigine) | VRTX | Diabetic Peripheral Neuropathic Pain | scheduled | "NCT06696443 (Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-25 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06696443)) |
| January 2027 | [Awiqli Flextouch (insulin icodec) primary completion](https://sec-api.dev/pdufa/insulin-icodec) | NVO | Diabetes Mellitus, Type 1 | scheduled | "NCT07076199 (A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-25 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07076199)) |
| January 2027 | [Rsvpref primary completion](https://sec-api.dev/pdufa/rsvpref) | PFE | Respiratory Syncytial Virus (RSV) | scheduled | "NCT07653100 (A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-25 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07653100)) |
| January 2027 | [Ff/umec/vi primary completion](https://sec-api.dev/pdufa/ff-umec-vi) | GSK | Asthma | scheduled | "NCT05757102 (A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-26 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05757102)) |
| January 28, 2027 | [INSMED Inc PDUFA date](https://sec-api.dev/companies/insm/catalysts) | INSM | MAC lung disease | scheduled | "Revenue† U.S. $75.5M +2% Int'l $48.9M +21% Worldwide $124.4M +9% sNDA granted priority review by FDA, with PDUFA target action date of January 28, 2027 Intend to submit data to PMDA in Q4:26 to support potential Japan label expansion Expect to launch under expanded all MACLD label in the U.S. & Japan in 1H:27* Combined TAM could expand to >200K patients‡ in the U.S. and Japan*" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126041097/ef20084500_ex99-2.htm)) |
| January 2027 | [Piqray (alpelisib) primary completion](https://sec-api.dev/pdufa/alpelisib) | NVS | Breast Cancer | scheduled | "NCT05038735 (Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-28 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05038735)) |
| January 2027 | [MRNA-1018-H5 primary completion](https://sec-api.dev/pdufa/mrna-1018-h5) | MRNA | Influenza | scheduled | "NCT07496450 (A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-28 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07496450)) |
| January 29, 2027 | [Cerebrum (cerebrum) PDUFA date](https://sec-api.dev/pdufa/cerebrum) | PRAX | essential tremor, or ET | scheduled | "For our ulixacaltamide program within the Cerebrum™ platform, we submitted a New Drug Application, or NDA, for ulixacaltamide HCl for the treatment of essential tremor, or ET, to the FDA based on the positive results of our two studies in the Phase 3 Essential3 program in ET, and it was accepted for review with a target action date under the Prescription Drug User Fee Act, or PDUFA, of January 29, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000089/prax-20260930.htm)) |
| January 2027 | [Piqray (alpelisib) primary completion](https://sec-api.dev/pdufa/alpelisib) | NVS | Breast Neoplasms | scheduled | "NCT04544189 (Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04544189)) |
| January 2027 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | C3G | scheduled | "NCT04817618 (Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04817618)) |
| January 2027 | [Disitamab vedotin primary completion](https://sec-api.dev/pdufa/disitamab-vedotin) | PFE | Urothelial Carcinoma | scheduled | "NCT05911295 (Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05911295)) |
| January 2027 | [Ziltivekimab primary completion](https://sec-api.dev/pdufa/ziltivekimab) | NVO | Cardiovascular Risk; Acute Myocardial Infarction (AMI) | scheduled | "NCT06118281 (ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06118281)) |
| January 30, 2027 | [Joenja® (leniolisib) PDUFA date](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | scheduled | "On September 28, 2026, we announced that the FDA had accepted this sNDA and granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2027." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000049/a2026q3pressrelease.htm)) |
| January 30, 2027 | [Pharming Group N.V. PDUFA date](https://sec-api.dev/companies/phar/catalysts) | PHAR |  | scheduled | "•PDUFA target action date of January 30, 2027" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000041/pharmingannouncesusfdaacce.htm)) |
| January 2027 | [Rabies vaccine primary completion](https://sec-api.dev/pdufa/rabies-vaccine) | SVA | Rabies (Healthy Volunteers) | scheduled | "NCT07055893 (Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-01-30 (ESTIMATED); Lead Sponsor Sinovac Biotech Co., Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07055893)) |
| January 2027 | [Scib1 or iscib1+ dna vaccine primary completion](https://sec-api.dev/pdufa/scib1-or-iscib1-dna-vaccine) | SCNLD | Malignant Melanoma; Melanoma (Skin); Melanoma Stage III | scheduled | "NCT04079166 (SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-31 (ESTIMATED); Lead Sponsor Scancell Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04079166)) |
| January 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Urinary Bladder Neoplasms | scheduled | "NCT04241185 (Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04241185)) |
| January 2027 | [Opsumit (macitentan) primary completion](https://sec-api.dev/pdufa/macitentan) | JNJ | Hypertension, Pulmonary | scheduled | "NCT05179876 (A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-31 (ESTIMATED); Lead Sponsor Actelion." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05179876)) |
| January 2027 | [QYLEKI (QRX003) primary completion](https://sec-api.dev/pdufa/qrx003) | QNRX | Netherton Syndrome | scheduled | "NCT07538583 (Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-01-31 (ESTIMATED); Lead Sponsor Quoin Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07538583)) |

Other months: https://sec-api.dev/fda-calendar/2026-12 , https://sec-api.dev/fda-calendar/2027-02. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates January 2027: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2027-01

```bibtex
@misc{secapidev_fda_calendar_2027_01_20261116,
  title        = {PDUFA dates January 2027: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2027-01}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2027_01_20261116","title":"PDUFA dates January 2027: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2027-01","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
